See more : Carbon Energy Corporation (CRBO) Income Statement Analysis – Financial Results
Complete financial analysis of Alaunos Therapeutics, Inc. (TCRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alaunos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Future Consumer Limited (FCONSUMER.NS) Income Statement Analysis – Financial Results
- Haad Thip Public Company Limited (HAATF) Income Statement Analysis – Financial Results
- Prakash Pipes Limited (PPL.BO) Income Statement Analysis – Financial Results
- Henry Schein, Inc. (HS2.DE) Income Statement Analysis – Financial Results
- Bharat Wire Ropes Limited (BHARATWIRE.NS) Income Statement Analysis – Financial Results
Alaunos Therapeutics, Inc. (TCRT)
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.00K | 2.92M | 398.00K | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Cost of Revenue | 4.80M | 2.76M | 740.00K | 1.13M | 629.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.80M | 163.00K | -342.00K | -1.13M | -629.00K | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Gross Profit Ratio | -95,960.00% | 5.58% | -85.93% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 16.28M | 25.02M | 49.64M | 52.70M | 38.33M | 34.13M | 45.08M | 157.79M | 106.79M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 773.14K | 8.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 120.00 |
| SG&A | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 120.00 |
| Other Expenses | 971.00K | 529.00K | -1.20M | 385.00K | 813.00K | 631.00K | 465.00K | 134.00K | 12.00K | -5.00K | -579.00K | -13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.39M | 0.00 | 0.00 | 486.00 | 42.51K | 74.14K |
| Operating Expenses | 29.47M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Cost & Expenses | 34.27M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.92M | 3.15M | 1.18M | 0.00 | 0.00 | 0.00 | 830.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.32M | 2.76M | 2.60M | 1.13M | 629.00K | 573.00K | 369.00K | 290.00K | 357.00K | 462.00K | 738.00K | 658.00K | 268.00K | 188.00K | 330.00K | 388.00K | 433.35K | 173.92K | 101.23K | 0.00 | 486.00 | 799.00 | 750.00 |
| EBITDA | -30.90M | -31.82M | -74.97M | -78.85M | -117.17M | -53.33M | -53.12M | -165.01M | -119.73M | -43.50M | -56.98M | -102.17M | -71.40M | -32.48M | -7.32M | -24.84M | -26.17M | -17.68M | -9.42M | -5.65M | -35.36K | -39.14K | -71.79K |
| EBITDA Ratio | -618,080.00% | -1,187.85% | -19,112.81% | 0.00% | 0.00% | -37,030.14% | -817.00% | -2,407.56% | -2,772.39% | -4,022.00% | -7,270.00% | -13,445.13% | -11,807.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,523.04% | -4,159.04% |
| Operating Income | -34.27M | -35.11M | -77.55M | -80.36M | 2.26M | -53.91M | -53.49M | -165.31M | -120.10M | -43.50M | -57.71M | -102.17M | -71.40M | -24.55M | -12.12M | -25.62M | -28.57M | -19.11M | -9.79M | -39.17K | -35.84K | -39.94K | -72.54K |
| Operating Income Ratio | -685,340.00% | -1,201.40% | -19,484.67% | 0.00% | 0.00% | -36,921.92% | -837.27% | -2,409.37% | -2,772.39% | -3,168.17% | -7,214.13% | -12,771.13% | -10,704.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Total Other Income/Expenses | -873.00K | -2.63M | -1.20M | 385.00K | -59.94M | 789.00K | -830.00K | 10.00K | 12.00K | 11.72M | 606.00K | 6.04M | 7.62M | -8.12M | 4.47M | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -35.14M | -37.73M | -78.75M | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | 0.00 | -17.86M | 0.00 | -39.17K | -35.84K | -39.94K | -72.54K |
| Income Before Tax Ratio | -702,800.00% | -1,291.24% | -19,786.68% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Income Tax Expense | 0.00 | -133.00K | -1.86M | -1.13M | 60.12M | -947.00K | 2.13M | 114.00K | -12.00K | -23.44M | -1.79M | -12.09M | -15.24M | 16.25M | -8.95M | -388.00K | -1.96M | -1.25M | -270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -35.14M | -37.60M | -76.89M | -78.85M | -177.92M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Net Income Ratio | -702,800.00% | -1,286.69% | -19,320.10% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| EPS | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.52 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| EPS Diluted | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.44 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| Weighted Avg Shares Out | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
| Weighted Avg Shares Out (Dil) | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 958.07K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the...
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the clinical-stage oncology-focused cell therapy company's Q3 earnings report. The Alaunos Therapeutics earnings report starts with earnings per share of -4 cents.
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Company is exploring strategic alternatives with Cantor Fitzgerald...
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic reprioritization to focus on its hunTR...
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial...
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be...
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31,...
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Source: https://incomestatements.info
Category: Stock Reports